Company Overview - Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative therapies for medically supervised settings [4] - The company's lead product candidate, Niyad™, is a lyophilized formulation of nafamostat, currently studied as an anticoagulant for the extracorporeal circuit and has received Breakthrough Device Designation from the FDA [4] - Talphera is also developing two pre-filled syringes in partnership with Aguettant: Fedsyra™, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe [4] Financial Results Announcement - Talphera will release its third quarter 2024 financial results after market close on November 13, 2024 [1] - A live webcast and conference call will be held at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Standard Time to discuss the results and provide a business update [1] Webcast and Conference Call Details - The webcast can be accessed through the Investors section of Talphera's website, and a replay will be available for 90 days following the event [2] - Investors can participate in the conference call by dialing 1-800-836-8184 for North American callers or 1-646-357-8785 for international callers, with a conference ID of 89949 [3]
Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024